These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 32998997)

  • 41. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
    Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
    Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
    Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
    Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
    Nair S; Mazzoccoli L; Jash A; Govero J; Bais SS; Hu T; Fontes-Garfias CR; Shan C; Okada H; Shresta S; Rich JN; Shi PY; Diamond MS; Chheda MG
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
    Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
    Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.
    Chryplewicz A; Scotton J; Tichet M; Zomer A; Shchors K; Joyce JA; Homicsko K; Hanahan D
    Cancer Cell; 2022 Oct; 40(10):1111-1127.e9. PubMed ID: 36113478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
    Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.
    Pearson JRD; Puig-Saenz C; Thomas JE; Hardowar LD; Ahmad M; Wainwright LC; McVicar AM; Brentville VA; Tinsley CJ; Pockley AG; Durrant LG; McArdle SEB
    Cancer Immunol Immunother; 2024 Jul; 73(9):178. PubMed ID: 38954031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
    Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
    J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted delivery of anti-miRNA21 sensitizes PD-L1
    Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH
    Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018
    [No Abstract]   [Full Text] [Related]  

  • 53. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
    Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
    Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
    Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
    Front Immunol; 2021; 12():650105. PubMed ID: 34394072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor.
    Yang Y; Li Z; Wang Y; Gao J; Meng Y; Wang S; Zhao X; Tang C; Yang W; Li Y; Bao J; Fan X; Tang J; Yang J; Wu C; Qin M; Wang L
    EMBO Mol Med; 2024 Apr; 16(4):885-903. PubMed ID: 38448544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.